Award
NIH Reporter #5U54CA283759-04
Acute myeloid leukemia (AML) Research Project
Recipient
National Cancer Institute (NCI), part of the National Institutes of Health (NIH)
Award Amount
$230,344.00
Ceiling
$230,344.00
Awarded
August 18, 2026
Identifier
5U54CA283759-04
Award for research on acute myeloid leukemia using patient-derived xenograft models to develop targeted therapies including Menin inhibitors.
Description
This project focuses on advancing the use of patient-derived xenograft (PDX) models for therapy development in acute myeloid leukemia (AML), with a focus on genetic subsets and targeted therapies such as Menin inhibitors.